Skip to main content

Pfizer-NCBiotech Distinguished Postdoctoral Fellowship in Gene Therapy (GTF)

Maximum Award: 

2017 Application Cycle Now Open

Application Deadline:  Wednesday, August 2, 2017 (noon)

Funds will be available beginning November 1, 2017

Proposals are now being accepted for the new Pfizer-NCBiotech Distinguished Postdoctoral Fellowship in Gene Therapy (Pfizer-GTF)

This unique program is a partnership between Pfizer, Inc. and the North Carolina Biotechnology Center that supports the scientific and professional development of exceptional postdoctoral fellows interested in establishing research careers in gene therapy. 

Competitive awards fund two-year fellowships that enable early-career scientists to conduct research in the laboratories of gene therapy-related investigators at any North Carolina university.

Eligible research projects will propose to:

  • Develop adeno-associated virus (AAV) gene therapy platforms or address challenges associated with the clinical application of these technologies;
  • Develop technologies or methodologies that support the design, application or manufacturing of AAV-based gene therapies; or
  • Explore novel applications of AAV-based gene therapies, such as target validation or preliminary testing of AAV constructs in monogenic rare disease models.

Pfizer-GTF fellowships feature professional development training in FDA regulations related to biological therapies, project management skills, scalable manufacturing of gene therapy products, intellectual property and entrepreneurship.

Applications are submitted by qualifying researchers with faculty appointments in any North Carolina university and must name a specific Fellow candidate.   

For details on eligibility and application instructions, see the Pfizer-GTF guidelines below.


Pfizer-GTF Application Guidelines and Instructions

Budget and Budget Justification Form


When you have your materials completed, submit your application online at this link.